People: Spectrum Pharmaceuticals Inc (SPPI.O)

Summary

Name	Age	Since	Current Position
Rajesh Shrotriya	68	2002	Chairman of the Board, President, Chief Executive Officer
Kurt Gustafson	45	2013	Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Ken Keller	49	2012	Chief Operating Officer, Executive Vice President
Brett Scott	61	2013	Senior Vice President - Finance
Gilles Gagnon	58	2012	Director
Anton Gueth	55	2012	Director
Luigi Lenaz	71	2010	Director
Krishan Arora	71	2010	Independent Director
Stuart Krassner	76	2004	Independent Director
Anthony Maida	61	2003	Independent Director

» Insider Trading

Biographies

Name	Description
Rajesh Shrotriya	Dr. Rajesh C. Shrotriya, M.D. has served as Chairman of the Board, President, Chief Executive Officer of Spectrum Pharmaceuticals Inc .,since August 2002. From September 2000 to August 2002, Dr. Shrotriya served as President and Chief Operating Officer of Spectrum. Dr. Shrotriya also serves as a member of the board of directors of Antares Pharma, Inc., an NYSE AMEX-listed drug delivery systems company. Prior to joining Spectrum, Dr. Shrotriya held the position of Executive Vice President and Chief Scientific Officer from November 1996 until August 2000, and as Senior Vice President and Special Assistant to the President from November 1996 until May 1997, for SuperGen, Inc., a publicly-held pharmaceutical company focused on drugs for life-threatening diseases, particularly cancer. From August 1994 to October 1996, Dr. Shrotriya held the positions of Vice President, Medical Affairs and Vice President, Chief Medical Officer of MGI Pharma, Inc., an oncology-focused biopharmaceutical company. Dr. Shrotriya spent 18 years at Bristol-Myers Squibb Company in a variety of positions, most recently as Executive Director, Worldwide CNS Clinical Research. Previously, Dr. Shrotriya held various positions at Hoechst Pharmaceuticals, most recently as Medical Advisor. Dr. Shrotriya was an attending physician and held a courtesy appointment at St. Joseph Hospital in Stamford, Connecticut. In addition, he received a certificate for Advanced Biomedical Research Management from Harvard University. Dr. Shrotriya received an M.D. from Grant Medical College, Bombay, India, in 1974; a D.T.C.D. (Post Graduate Diploma in Chest Diseases) from Delhi University, V.P. Chest Institute, Delhi, India, in 1971; an M.B.B.S. (Bachelor of Medicine and Bachelor of Surgery -- equivalent to an M.D. degree in the U.S.) from the Armed Forces Medical College, Poona, India, in 1967; and a B.S. in Chemistry from Agra University, Aligarh, India, in 1962.
Kurt Gustafson	Mr. Kurt A. Gustafson has been appointed as the Chief Financial Officer, Executive Vice President, Principal Accounting Officer of Spectrum Pharmaceuticals, Inc., with effect from June 3, 2013. Mr. Gustafson has more than twenty years’ experience in the pharmaceutical industry. Since 2009, Mr. Gustafson has served as Vice President and Chief Financial Officer of Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, oncology, dermatology, and drug delivery markets. Prior to joining Halozyme, Mr. Gustafson gained operational and managerial experience in financial planning and analysis, accounting, treasury and international responsibility during his 18 years with Amgen Inc. In his most recent position with Amgen, as Vice President, Manufacturing Finance, Mr. Gustafson had financial responsibility for each of Amgen’s worldwide manufacturing sites and the Cost Accounting Group. From 2004 to 2006, Mr. Gustafson was Vice President, Finance and CFO of Amgen International, responsible for financial planning and accounting for Ex-US operations. Stationed in Switzerland, Mr. Gustafson was responsible for Amgen’s International Operations, which spanned Europe, the Middle East, Eastern Europe, North Africa and Australia. From 2000 to 2004, Mr. Gustafson headed up Corporate Financial Planning and Analysis, most recently as Vice President, Corporate Financial Planning & Analysis. From 1991 to 2000, Mr. Gustafson held multiple positions in Amgen’s Treasury group with increasing levels of responsibility, most recently serving as Treasurer, where he oversaw the tax department and the customer finance group. Prior to joining Amgen, Mr. Gustafson worked in public accounting as Staff Auditor at Laventhol & Horwath in Chicago. He earned a B.A. in accounting from North Park University in Chicago and an M.B.A. from University of California, Los Angeles.
Ken Keller	Mr. Ken Keller is appointed as the Chief Operating Officer, Executive Vice President of Spectrum Pharmaceuticals, Inc. Prior to joining the Company, Mr. Keller spent 21 years at Amgen. His most recent role was Vice President and General Manager, Bone Health Business Unit. During his career at Amgen, Mr. Keller has been the Marketing Lead or the General Manager for four of the world’s top selling biologic medicines Neupogen, Neulasta®, Aranesp® and Enbrel. He also has international experience, as Managing Director for Amgen’s United Kingdom and Ireland affiliate. Mr. Keller holds a Bachelors of Science degree in Business from Saint Johns University and a Masters in Business Administration from Loyola Marymount University.
Brett Scott	Mr. Brett L. Scott is Senior Vice President - Finance of Spectrum Pharmaceuticals, Inc., since June 5, 2013. Previously Mr. Scott served as Chief Financial Officer at Biolase Technology a Southern California-based medical device company. Prior to Biolase, Mr. Scott was Executive Vice President and Chief Financial Officer of North American Scientific, Inc., a Southern California-based medical device company. In March 2009, North American Scientific sought protection under Chapter 11 of the U.S. Bankruptcy Code, and as part of an orderly plan to sell its assets, during the following two months completed the sale of its prostate and breast cancer businesses to Best Theratronics, Ltd. and Portola Medical Inc. respectively. Prior to North American Scientific, Mr. Scott was Chief Financial Officer of Irvine, California-based Alsius Corporation from January 2006 to August 2008. Mr. Scott is a Certified Public Accountant and received a bachelor of science degree in business administration from the University of Southern California.
Gilles Gagnon	Mr. Gilles Gagnon has been appointed as Director of Spectrum Pharmaceuticals, Inc., effective March 27, 2012. Prior to joining Spectrum, Mr. Gagnon was the President and Chief Executive Officer of Æterna Zentaris (AEZS), a Nasdaq listed Company. He is currently President of Spectrum Pharma Canada Inc., an affiliate of Spectrum, and has served in such position since September 2008. Prior to his current position, he served as Vice President Corporate Development at Æterna Zentaris, a biopharmaceutical company focused in oncology and endocrinology, since 1999, became President and Chief Operating Officer in 2001 and then President and Chief Executive Officer in January 2003 following the acquisition of Æterna Zentaris from German-based Degussa AG in December 2002. Prior to joining Æterna Zentaris, he was VP, External Affairs for Novartis Pharma Canada Inc. from 1996 to 1999. Prior to that, from 1989 to 1996, Mr. Gagnon held various positions including Executive Director, Corporate Planning and Business Development, Senior Director, Strategic Alliances, General Manager, Governments Affairs and Access to Market and Director of Professional Services at Sandoz Pharmaceuticals Inc. He started his career at Atomic Energy of Canada as a sales representative for the Radiopharmaceutical Division. Mr. Gagnon is regularly invited to speak at many management conferences and is co-author of numerous scientific and business related articles. Throughout his career in the pharmaceutical industry, Mr. Gagnon was especially involved in corporate development, alliance management, as well as marketing functions where he participated in the launch of nine innovative pharmaceutical products, in addition to his general management functions.
Anton Gueth	Mr. Anton Gueth is the Director of Spectrum Pharmaceuticals Inc. Mr. Gueth’s pharmaceutical experience was gained primarily at Eli Lilly and Company where he spent 19 years in increasing various executive positions, including as a managing director and in marketing and sales. After leaving Eli Lilly and Company he worked as a managing director at Burrill & Company, a merchant bank specialized in the healthcare field. Since September 2011, Mr. Gueth has served as President of Gueth Consulting LLC, which provides licensing, mergers and acquisitions and financial advisory services to companies in the pharmaceutical industry. From January 2007 to September 2011, he was a Managing Director of Burrill & Company, a merchant bank specialized in the health care field. His career includes nearly 19 years with Eli Lilly and Company, most recently as director of Alliance Management. He also served as General Manager of Eli Lilly’s African and Middle Eastern operations; Vice President of Financial Planning and Treasury of PCS Health Systems; Managing Director of Eli Lilly’s Saudi Arabia, Gulf and Yemen operations, as well as other sales, marketing and financial positions. Mr. Gueth has been a director of Antares Pharma, Inc., an NYSE AMEX Equities-listed drug delivery systems company, since 2003, where he is the Chairman of the Compensation Committee and also serves on the Audit and Governance Committees. Mr. Gueth is a director of the American Liver Foundation, Northern California Chapter. Mr. Gueth earned a Masters Degree in agricultural economics from the Justus Liebig University in Giessen, Germany, as well as a Masters Degree in public affairs from Indiana University.
Luigi Lenaz	Dr. Luigi Lenaz, M.D. has served as Director of Spectrum Pharmaceuticals, Inc., since June 2010. Dr. Lenaz served as Spectrum’s Chief Scientific Officer from February 2005 to June 2008 and as President of Spectrum’s Oncology Division from 2000 to 2005. Since retiring as Spectrum’s Chief Scientific Officer in June 2008, Dr. Lenaz provided consulting services to Spectrum from June 2008 to June 2010. From 1997 to 2000, Dr. Lenaz served as Senior Vice President of Clinical Research, Medical Affairs at SuperGen, Inc., a NASDAQ listed pharmaceutical company dedicated to cancer drug development. From 1978 to 1997, Dr. Lenaz held several senior management positions with Bristol- Myers Squibb, a NYSE-listed pharmaceutical company, including Senior Vice President of Oncology Franchise Management from 1990 to 1997 and Director of Scientific Affairs, Anti-Cancer from 1985 to 1990. Dr. Lenaz is also a prominent researcher, having conducted research in the areas of pharmacology, experimental chemotherapy, histology, general physiology, and experimental therapeutics at various institutions for cancer research, including Roswell Park Memorial Institute, Memorial Sloan-Kettering Cancer Center and the National Cancer Institute in Milan. He is a member of several scientific societies, including the American Association for Cancer Research, American Association for Clinical Oncology, European Society for Medical Oncology, and International Association for the Study of Lung Cancer. Dr. Lenaz has served as a director of Pharmaco-Kinesis Corporation, a privately held medical device company, since January 2009. Dr. Lenaz is a graduate of Liceo Scientifico A. Righi in Bologna, Italy and he received a medical degree from the University of Bologna Medical School in 1966.
Krishan Arora	Dr. Krishan K. Arora, Ph.D. is Independent Director of Spectrum Pharmaceuticals, Inc. Prior to his election, Dr. Arora had been providing consulting services to Spectrum since February 2010. Dr. Arora is a business executive with global experience in driving strategic thinking, management and implementation of operations for drug development worldwide. Dr. Arora has provided consulting services to senior management at several pharmaceutical companies, including Astellas Pharma Global Development, Inc., for global drug development, from May 2008 to June 2009, and UCB, Inc., for applications in global regulatory affairs, electronic document management, pharmacovigilance and worldwide quality assurance and compliance, from November 2003 to February 2006. Prior to that, Dr. Arora held senior management positions with several pharmaceutical companies, including Vice President of R&D Global Regulatory Affairs for Management Information at Pfizer Inc. from 1998 to 2003, Senior Director of Regulatory Affairs at Novartis AG from 1993 to 1998 and Group Director of Biometrics Operations at Sanofi-Aventis. In addition, from 1994 to 2003, Dr. Arora served as Chairman of the Electronic Regulatory Submissions Working Group at PhRMA, which consisted of business and information technology experts from the FDA and 20 biopharmaceutical companies and was the PhRMA lead at ICH on establishing electronic standards for submission of marketing applications to regulatory authorities. Dr. Arora received a B.Sc. in Mathematics, Physics and Chemistry from Lucknow University in India, a B.Sc. (Honors) in Agriculture and a M.Sc. in Animal Genetics from G. B. Pant University of Agriculture & Technology in India and a Ph.D. in Population Genetics from Iowa State University.
Stuart Krassner	Dr. Stuart M. Krassner, Sc.D., Psy.D, is Independent Director of Spectrum Pharmaceuticals Inc., since December 2004. He was previously a member of the Scientific Advisory Board from 1996 to 2001. Dr. Krassner’s career spans four decades of experience in various positions at the University of California, Irvine, or UCI, most recently as Professor Emeritus of Developmental and Cell Biology at the School of Biological Sciences. While at UCI, he developed and reinforced FDA and NIH compliance procedures for UCI-sponsored human clinical trials, established UCI’s first Institutional Review Board, and at one time headed all contract and grant activities. Dr. Krassner has also been retained by a number of public and private pharmaceutical, medical device and other companies to provide scientific and regulatory advisory services, including FDA compliance. Dr. Krassner’s work has been published in numerous peer-reviewed U.S. journals. Dr. Krassner has been awarded grants from the National Institute of Health, the National Science Foundation and the World Health Organization. Dr. Krassner has been a member of the American Society of Protozoology, the American Society of Tropical Medicine and Hygiene, the Corporation of the Marine Biological Laboratories, Woods Hole, MA, and Sigma Xi, among others. Dr. Krassner received a B.S. in Biology from Brooklyn College and an Sc.D. from the Bloomberg School of Public Health at Johns Hopkins University.
Anthony Maida	Dr. Anthony E. Maida, III, M.A., M.B.A., Ph.D. has served as Independent Director of Spectrum Pharmaceuticals Inc., since December 2003. Dr. Maida is currently Chief Operation Officer for Northwest Biotherapeutics, Inc., a cancer vaccine company focused on therapy for patients with glioblastoma multiforme and prostate cancer. He is responsible for the oversight of the operations of Northwest Biotherapeutics. Dr. Maida was formerly Vice President of Clinical Research and General Manager, Oncology, World-wide for PharmaNet, Inc. Prior to joining Pharmanet, Dr. Maida served as Chairman, Founder and Director of BioConsul Drug Development Corporation and Principal of Anthony Maida Consulting International, servicing pharmaceutical firms, venture capital, hedge funds and Wall Street, in the clinical development of therapeutic products and product/company acquisitions. Dr. Maida’s skill set includes the execution and oversight of finance, operations, research, and commercial clinical and scientific development, regulatory and manufacturing for the development of various therapeutic modalities. He is an expert in ‘virtual’ development and cost-cutting of operations in large and small biotechnology companies. From 1992 to September of 1999, Dr. Maida was President and Chief Executive Officer of Jenner Biotherapies, Inc. Dr. Maida was formerly a board member for Sirion Therapeutics, Inc. and GlycoMetrix, Inc. Dr. Maida holds a B.A. degree in Biology, a B.A. degree in History, a MBA, a MA in toxicology and Ph.D in Immunology. He is a member of the American Society of Clinical Oncology, the American Association for Cancer Research, the Society of Neuro-Oncology, the International Society for Biological Therapy of Cancer and the American Chemical Society. Dr. Maida holds a number of patents and patent applications associated with various therapeutic modalities and approaches.

Basic Compensation

Name	Fiscal Year Total
Rajesh Shrotriya	25,215,800
Kurt Gustafson	--
Ken Keller	--
Brett Scott	1,568,200
Gilles Gagnon	--
Anton Gueth	--
Luigi Lenaz	1,596,320
Krishan Arora	--
Stuart Krassner	--
Anthony Maida	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
Rajesh Shrotriya	1,777,436	964,303
Kurt Gustafson	0	0
Ken Keller	0	0
Brett Scott	0	0
Gilles Gagnon	0	0
Anton Gueth	0	0
Luigi Lenaz	584,150	494,704
Krishan Arora	0	0
Stuart Krassner	0	0
Anthony Maida	0	0

Insider Trading

Name	Shares Traded	Price
GUSTAFSON KURT A	100,000	$0.00
MAIDA ANTHONY E III	5,000	$3.92
MAIDA ANTHONY E III	5,000	$11.50
MAIDA ANTHONY E III	1,700	$3.92
MAIDA ANTHONY E III	3,300	$12.25
MAIDA ANTHONY E III	3,300	$4.26
MAIDA ANTHONY E III	1,700	$12.25
SHROTRIYA RAJESH C	23,344	$11.66
MAIDA ANTHONY E III	5,000	$4.26
MAIDA ANTHONY E III	5,000	$11.42
SHROTRIYA RAJESH C	205,836	$11.24
SHROTRIYA RAJESH C	172,507	$11.35
SHROTRIYA RAJESH C	10,000	$0.00
SHROTRIYA RAJESH C	2,823	$0.00
SHROTRIYA RAJESH C	10,000	$0.00
SHROTRIYA RAJESH C	14,728	$11.34
KRASSNER STUART MITCHELL	10,000	$11.34
GAGNON GILLES	10,000	$11.34
MAIDA ANTHONY E III	10,000	$11.34
LENAZ LUIGI	2,800	$11.34
SHROTRIYA RAJESH C	163,139	$11.34
MAIDA ANTHONY E III	4,700	$11.34
LENAZ LUIGI	10,000	$11.34
ARORA KRISHAN K	10,000	$11.34
GUETH ANTON G	10,000	$11.34

» Full list on Insider Trading

People: Spectrum Pharmaceuticals Inc (SPPI.O)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: